Neurocrine Biosciences (NBIX) jumps 43% AH as the company says the small molecule VMAT2 inhibitor NBI-98854 hit its primary endpoint in Kinect 2.
Week 6 AIMS scores: -2.6 points for the ITT group and -0.2 points for placebo — that's good for p<0.001.
Responder rate: 49% versus 18% in placebo for p<0.002.
"The profound response in this Kinect 2 study demonstrates the potential of NBI-98854 as both a safe and highly effective treatment for patients suffering from tardive dyskinesia," the company notes.
NBIX will now finalize the initial draft for Phase 3 protocol which it expects to file in H1. (PR)